Enhanced killing of the combination-treated cells was accompanied by a clear increase in cleaved PARP (Fig. 1k), a marker of pro-apoptotic caspase activation, showing that the drug combination induces apoptosis in these TP53 wild-type AML cells. The gene discussed is TP53; the disease is acute myeloid leukemia.